Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data.
about
The retinoid X receptors and their ligandsChemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agentsRetinoic acid actions through mammalian nuclear receptors.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.Dual induction of caspase 3- and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells.Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial.Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin:retinol acyltransferase-deficient mice primarily through retinoid actions immediately after carcinogen administration.Hepatic metabolism of retinoids and disease associationsMolecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cellsCombination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for Hepatocellular Carcinoma (HCC).Retinoids and rexinoids in cancer prevention: from laboratory to clinic.Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic MalignanciesSynergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment.Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis.Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids.Postoperative therapy options for hepatocellular carcinoma.S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model.Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells.CYP4A11 is repressed by retinoic acid in human liver cells.Lycopene attenuated hepatic tumorigenesis via differential mechanisms depending on carotenoid cleavage enzyme in mice.The CD133+CD44+ precancerous subpopulation of oval cells is a therapeutic target for hepatocellular carcinoma.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group.Synergistic growth inhibition in HL-60 cells by the combination of acyclic retinoid and vitamin K2.Chemoprevention of liver carcinogenesis with retinoids: Basic and clinical aspects.Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor.
P2860
Q24562747-C8855865-5D32-4BA8-B791-27F41C85F89EQ26772302-CB34E4ED-2BCB-4C85-A250-5958B1E86848Q30408649-67004D14-F539-45AB-A8BD-939C516AB0A0Q30479629-78B6134F-C68E-4A2C-821E-553271F38C4BQ33866448-E310FDEF-688F-4EC3-9692-3DE20F90C96BQ34506882-C8EF62EF-E5A2-47E5-9D24-704650BF2972Q35698198-6FDD588E-648C-4F7B-8AAA-B37CEAA61E30Q35730616-6EA5D681-EF19-47B2-AF0D-1FF25A34C443Q36368963-0D7AB8B4-3A3C-42BB-BD83-920294EAF2CFQ36485122-4970A142-09F8-43B4-9269-7704131C0E61Q36664787-49DAE873-4311-4E5C-9E4C-9761359BF79CQ36680198-38D3A6F5-12FA-42E4-A734-3000F460680EQ36917809-524A6AE0-4FFE-4CB5-8893-153BB4A41E47Q37182802-20BCF974-5F7F-42E5-B40E-D0D5C01F27D5Q38066478-24E355A6-3B7A-417A-A4FE-5991A0B115A6Q38165918-4D725532-59B4-4D31-B074-E25177166B44Q38203306-7AE227F0-D9C0-4B55-ABBD-8BE4961EAF05Q39851067-A2421190-AC37-4DEF-AD1A-2E080D3939ACQ40176027-7BC15A7F-A5F1-467B-B328-2C30247CCC6FQ40277767-59BDEB30-C8F6-4A66-9064-D572141235C4Q41850183-8AE64A83-48F7-43EA-8411-BC704D46CFB4Q41871003-84816220-73BF-4579-A052-70E181A9776CQ41962614-27132C16-3310-4960-A1F1-13C31E080C36Q42156187-35B47BA2-7B96-4AF8-9F6F-1D1567F14D4DQ50443179-4929D107-AC8A-431A-BB0F-A52E6B30BC38Q52582219-8D782FAC-F92B-4D3F-8293-51E91748DA9BQ53343711-A810D841-3117-4513-B334-05D5B7F7A47C
P2860
Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Prevention of second primary t ...... the long-term follow-up data.
@ast
Prevention of second primary t ...... the long-term follow-up data.
@en
type
label
Prevention of second primary t ...... the long-term follow-up data.
@ast
Prevention of second primary t ...... the long-term follow-up data.
@en
prefLabel
Prevention of second primary t ...... the long-term follow-up data.
@ast
Prevention of second primary t ...... the long-term follow-up data.
@en
P2093
P2860
P356
P1433
P1476
Prevention of second primary t ...... the long-term follow-up data.
@en
P2093
Hisashi Tsurumi
Hisataka Moriwaki
Ichiro Yasuda
Koji Takai
Masataka Okuno
Rie Matsushima-Nishiwaki
Takahiro Uematsu
Yasutoshi Muto
Yoshimune Shiratori
P2860
P356
10.1159/000082093
P577
2005-01-01T00:00:00Z